全身化疗联合支气管镜下种植术治疗晚期肺癌的临床研究。

Clinical Research on Systemic Chemotherapy Combined With Bronchoscopic Seed Implantation in the Treatment of Advanced Lung Cancer.

机构信息

Department of Pulmonary and Critical Care Medicine, Cangzhou People's Hospital, Cangzhou, China.

Department of Radiation Oncology, Cangzhou People's Hospital, Cangzhou, China.

出版信息

Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971600. doi: 10.1177/1533033820971600.

DOI:10.1177/1533033820971600

PMID:33280522

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7724264/

Abstract

OBJECTIVE

This study aims to explore the clinical value of systemic chemotherapy combined with bronchoscopic seed implantation in advanced lung cancer treatment.

METHODS

The study enrolled 253 patients with advanced lung cancer in Cangzhou People's Hospital from March 2018 to March 2020, and they were divided into test group and control group. Test group was given systemic chemotherapy combined with bronchoscopic seed implantation, while control group was given systemic chemotherapy. The objective response rate of tumor (ORR), disease control rate (DCR), serum tumor marker level, survival time and adverse reactions of 2 groups were compared.

RESULTS

After treatment, the levels of serum tumor markers including carcino-embryonic antigen, neuro-specific enolase, cytokeratin-19 and pro-gastrin-releasing peptide were markedly decreased in test group compared with those in control group ( < 0.05). Therein, the serum tumor marker level of non-small cell lung cancer (NSCLC) patients was significant decreased compared with that of small cell lung cancer (SCLC) patients in test group. Meanwhile, in test group, the serum tumor marker level of lung adenocarcinoma (LUAD) patients was significant decreased compared with that of lung squamous cell carcinoma (LUSC, < 0.05). The ORR and DCR in test group were superior to those in control group (63.4%, 92.5% 38.7%, 72.3%, < 0.05), while those were much higher in patients with NSCLC and LUAD relative to those in patients with SCLC and LUSC, respectively ( < 0.05). Furthermore, the progression-free survival (PFS) and overall survival (OS) in test group were significantly greater than those in control group. In test group, the PFS and OS of patients with NSCLC and LUAD were higher than those of patients with SCLC and LUSC.

CONCLUSION

The efficacy of systemic chemotherapy combined with bronchoscopic seed implantation was superior to that of systemic chemotherapy, which is worthy of promoting in clinical practice.

摘要

目的

本研究旨在探讨全身化疗联合支气管镜下种子植入术治疗晚期肺癌的临床价值。

方法

选取 2018 年 3 月至 2020 年 3 月沧州市人民医院收治的 253 例晚期肺癌患者，分为试验组和对照组。试验组给予全身化疗联合支气管镜下种子植入术，对照组给予全身化疗。比较两组患者的肿瘤客观缓解率（ORR）、疾病控制率（DCR）、血清肿瘤标志物水平、生存时间及不良反应。

结果

治疗后，试验组患者血清肿瘤标志物癌胚抗原、神经元特异性烯醇化酶、细胞角蛋白 19 及胃泌素释放肽前体水平均明显低于对照组（ < 0.05），其中非小细胞肺癌（NSCLC）患者血清肿瘤标志物水平显著低于小细胞肺癌（SCLC）患者，肺腺癌（LUAD）患者血清肿瘤标志物水平显著低于肺鳞状细胞癌（LUSC）患者。同时，试验组患者 ORR 和 DCR 均优于对照组（63.4%、92.5% 38.7%、72.3%， < 0.05），而 NSCLC 和 LUAD 患者的 ORR 和 DCR 明显高于 SCLC 和 LUSC 患者（ < 0.05）。此外，试验组患者无进展生存期（PFS）和总生存期（OS）均明显长于对照组。在试验组中，NSCLC 和 LUAD 患者的 PFS 和 OS 均高于 SCLC 和 LUSC 患者。